Hideki Kazuno

535 total citations
15 papers, 445 citations indexed

About

Hideki Kazuno is a scholar working on Molecular Biology, Rheumatology and Oncology. According to data from OpenAlex, Hideki Kazuno has authored 15 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Rheumatology and 4 papers in Oncology. Recurrent topics in Hideki Kazuno's work include Biochemical and Molecular Research (5 papers), Glycogen Storage Diseases and Myoclonus (3 papers) and Liver physiology and pathology (3 papers). Hideki Kazuno is often cited by papers focused on Biochemical and Molecular Research (5 papers), Glycogen Storage Diseases and Myoclonus (3 papers) and Liver physiology and pathology (3 papers). Hideki Kazuno collaborates with scholars based in Japan. Hideki Kazuno's co-authors include Norihiko Suzuki, Tomohiro Emura, Masakazu Fukushima, Yukio Tada, Tetsuji Asao, Shingo Yano, H. Tsujimoto, Yuko Murakami, Keiichi Nomura and Eiichi Yoshii and has published in prestigious journals such as Cancer Research, Biochemical Pharmacology and European Journal of Cancer.

In The Last Decade

Hideki Kazuno

15 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hideki Kazuno Japan	7	238	220	80	74	60	15	445
Akio Fujioka Japan	13	362 1.5×	206 0.9×	46 0.6×	122 1.6×	54 0.9×	21	518
Nienke Losekoot Netherlands	11	160 0.7×	217 1.0×	38 0.5×	66 0.9×	54 0.9×	14	400
Naoto Ohi Japan	12	169 0.7×	276 1.3×	86 1.1×	30 0.4×	100 1.7×	19	519
Young‐Choon Moon United States	10	235 1.0×	451 2.0×	84 1.1×	48 0.6×	140 2.3×	23	661
John Waas United States	4	193 0.8×	261 1.2×	72 0.9×	48 0.6×	87 1.4×	6	487
Kim Edmonds United Kingdom	9	317 1.3×	222 1.0×	48 0.6×	84 1.1×	75 1.3×	16	560
Beverly A. Teicher United States	15	240 1.0×	387 1.8×	37 0.5×	79 1.1×	133 2.2×	32	665
Todd Miller United States	4	139 0.6×	267 1.2×	179 2.2×	107 1.4×	64 1.1×	6	547
Carol A. Cucchi United States	11	310 1.3×	445 2.0×	69 0.9×	53 0.7×	92 1.5×	15	734
Tomohiro Emura Japan	10	583 2.4×	312 1.4×	49 0.6×	171 2.3×	96 1.6×	11	783

Countries citing papers authored by Hideki Kazuno

Since Specialization

Citations

This map shows the geographic impact of Hideki Kazuno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Kazuno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Kazuno more than expected).

Fields of papers citing papers by Hideki Kazuno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Kazuno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Kazuno. The network helps show where Hideki Kazuno may publish in the future.

Co-authorship network of co-authors of Hideki Kazuno

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Kazuno. A scholar is included among the top collaborators of Hideki Kazuno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Kazuno. Hideki Kazuno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Ito, Satoru, Sachie Otsuki, Hirokazu Ohsawa, et al.. (2023). Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use. ACS Medicinal Chemistry Letters. 14(4). 396–404. 16 indexed citations

Tada, Yukio, Hideki Kazuno, Tsutomu Sato, et al.. (2017). Molecular modeling study of the thymidine phosphorylase inhibitor by SBDD and classical QSAR analysis. 17(0). 19–29. 1 indexed citations

Kazuno, Hideki, Tatsushi Yokogawa, Kazuki Sakamoto, et al.. (2014). 29 TAS-114 is a novel dUTPase/DPD inhibitor, its DPD inhibition reduces capecitabine dosage but does not diminish therapeutic window in human tumor xenografts. European Journal of Cancer. 50. 15–15. 1 indexed citations

Sakamoto, Kazuki, Hideki Kazuno, Hiroyuki Ueno, et al.. (2014). 27 TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer. European Journal of Cancer. 50. 15–15. 3 indexed citations

Fujita, Hidenori, Kazutaka Miyadera, Masanori Kato, et al.. (2013). The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile. Molecular Cancer Therapeutics. 12(12). 2685–2696. 30 indexed citations

Nakatsuru, Yoko, Haruhisa Fujita, Hiroshi Sootome, et al.. (2012). 383 Significant in Vivo Antitumor Activity by a Highly Potent, Irreversible FGFR Inhibitor, TAS-2985. European Journal of Cancer. 48. 117–117. 1 indexed citations

Fujita, Hidenori, Kazutaka Miyadera, Kimihiro Ito, et al.. (2011). Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile. Cancer Research. 71(8_Supplement). 3577–3577. 1 indexed citations

Fujita, Hidenori, Kimihiro Ito, Toru Takenaka, et al.. (2011). Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis. Cancer Research. 71(8_Supplement). 3600–3600. 2 indexed citations

Yano, Shingo, Hideki Kazuno, Tsutomu Sato, et al.. (2004). Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: Optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase. Bioorganic & Medicinal Chemistry. 12(13). 3443–3450. 48 indexed citations

10.

Yano, Shingo, Hideki Kazuno, Norihiko Suzuki, et al.. (2004). Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: Discovery of novel orally active inhibitors of human thymidine phosphorylase. Bioorganic & Medicinal Chemistry. 12(13). 3431–3441. 28 indexed citations

11.

Fukushima, Masakazu, Norihiko Suzuki, Tomohiro Emura, et al.. (2000). Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochemical Pharmacology. 59(10). 1227–1236. 198 indexed citations

12.

Murakami, Yuko, Hideki Kazuno, Tomohiro Emura, et al.. (2000). Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.. International Journal of Oncology. 17(2). 277–83. 84 indexed citations

13.

Kazuno, Hideki, et al.. (1993). The first total synthesis of tetronasin (M139603). Tetrahedron Letters. 34(13). 2183–2186. 26 indexed citations

14.

Nomura, Keiichi, et al.. (1990). Syntheses of the tetrahydrofuran subunits of tetronasin and tetronomycin.. Chemical and Pharmaceutical Bulletin. 38(6). 1778–1780. 4 indexed citations

15.

Kazuno, Hideki. (1982). Dopamine-induced cyclic AMP increase in canine myocardium, kidney and superior mesenteric artery.. PubMed. 36(2). 99–112. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact